Omega-6 / Omega-3 Ratio

The omega-6 to omega-3 ratio (also written n-6/n-3 or ω-6/ω-3) compares the relative amounts of two essential families of polyunsaturated fatty acids (PUFAs) measured in your blood or tissues. They’re called “essential” because your body can’t make them—you must get them from food. Omega-6 fats include linoleic acid (LA) (abundant in many vegetable oils, nuts, and seeds), which can be converted into longer-chain omega-6 fats such as arachidonic acid (AA). Omega-3 fats include alpha-linolenic acid (ALA) (from flaxseed, chia, walnuts and some plant oils) and the longer-chain marine omega-3s EPA and DHA found mainly in fatty fish and seafood.

Both omega-6 and omega-3 fats are built into your cell membranes and are used to make signalling molecules (including eicosanoids) that influence inflammation, blood clotting, blood vessel tone, immune activity, and tissue repair. Because omega-6 and omega-3 fats share the same conversion enzymes, they “compete” metabolically, and the ratio can reflect which pathway dominates over time. While both families are important, an imbalanced pattern—often seen with high omega-6 oil intake and low marine omega-3 intake—can shift the mix of downstream signalling molecules toward a profile that may be less favourable in some individuals or contexts.

The omega-6 to omega-3 ratio is relevant because it provides insight into the overall inflammatory balance of your body, which plays a central role in cardiovascular disease, metabolic dysfunction, immune regulation, and chronic disease risk. Inflammation is not inherently harmful—it is a necessary biological response—but chronically elevated, unresolved inflammation is a major driver of atherosclerosis, insulin resistance, fatty liver disease, and many inflammatory conditions.

Early observational and clinical studies suggested that high omega-6 to omega-3 ratios, characteristic of modern Western diets, were associated with higher rates of cardiovascular disease, autoimmune disorders, cancer, asthma, osteoporosis, and metabolic disease, while lower ratios were associated with reduced mortality and improved inflammatory outcomes. In certain disease contexts, ratios closer to 2–5:1 were associated with reduced inflammatory markers and improved clinical outcomes, while ratios above 10:1 were associated with worse cardiometabolic profiles.

However, more recent randomized controlled trials and large population studies have demonstrated that the relationship is more nuanced than previously thought. Increasing omega-6 intake alone—particularly linoleic acid—does not consistently increase inflammation, oxidative stress, or cardiometabolic risk when omega-3 intake is adequate. In fact, both omega-6 and omega-3 polyunsaturated fats are independently associated with lower cardiovascular disease risk. This has shifted scientific understanding away from viewing omega-6 fats as inherently harmful and toward recognizing that absolute omega-3 intake and the balance between specific fatty acids may be more important than the ratio alone.

Despite this, evidence still supports the clinical relevance of fatty acid balance in specific contexts. Studies measuring fatty acids in adipose tissue (a marker of long-term intake) show that ratios between omega-3-derived EPA and DHA relative to arachidonic acid predict cardiovascular risk more accurately than omega-3 levels alone. Individuals with lower omega-6/omega-3 ratios often demonstrate reduced expression of inflammatory genes, improved lipid profiles, better insulin sensitivity, and lower markers of liver inflammation. High omega-6/omega-3 ratios have been linked to adverse cardiometabolic profiles, including higher triglycerides, LDL cholesterol, insulin resistance, fatty liver index, and inflammatory oxylipins derived from arachidonic acid.

The ratio also influences the production of bioactive lipid mediators such as prostaglandins, leukotrienes, resolvins, protectins, and maresins. Higher ratios favor pro-inflammatory mediators, while lower ratios favor molecules that actively resolve inflammation and support tissue repair. Genetic differences further modify how individuals respond to different ratios, meaning optimal balance varies between people. For this reason, the omega-6/omega-3 ratio should be interpreted as a contextual biomarker—most useful when considered alongside absolute omega-3 intake, inflammatory markers, lipid profiles, and metabolic health.

• Optimal: 3:1 to 5:1

• Borderline (mildly unbalanced): 6:1 to 9:1

• High: 10:1 to 15:1

• Very high: >15:1

The omega-6/omega-3 ratio is driven primarily by dietary intake, as the body cannot synthesize either fatty acid family. The largest contributors to a high ratio are omega-6-rich vegetable oils such as corn, sunflower, safflower, soybean, cottonseed, and many processed and restaurant foods prepared with these oils. Nuts, seeds, grain-fed meats, poultry, salad dressings, mayonnaise, baked goods, and snack foods also contribute substantially to omega-6 intake in modern diets.

Low omega-3 intake is the other major driver. Plant-based omega-3 (ALA) from flaxseed, chia, hemp seeds, walnuts, and certain oils can contribute modestly, but conversion of ALA to EPA and DHA is limited—especially in individuals with insulin resistance, chronic inflammation, or certain genetic variants. As a result, marine-derived EPA and DHA from fatty fish and seafood are the most effective way to improve omega-3 status and lower the ratio.

Lifestyle and metabolic factors also influence fatty acid metabolism. Obesity, insulin resistance, metabolic syndrome, and type 2 diabetes alter enzyme activity and fatty acid storage, often worsening functional fatty acid balance. Chronic stress, poor sleep, smoking, and oxidative stress can degrade polyunsaturated fats and shift inflammatory signaling. Genetic variants in fatty acid desaturase enzymes (FADS genes) affect how efficiently omega-6 and omega-3 fats are converted and incorporated into tissues, meaning some individuals require higher direct intake of marine omega-3s to achieve balance.

Micronutrient status also plays a role. Enzymes involved in fatty acid metabolism rely on cofactors such as magnesium, zinc, iron, vitamin B6, and niacin. Antioxidants such as vitamin E, vitamin C, selenium, and polyphenols help protect fragile omega-3 fats from oxidative damage, preserving their biological activity.

If your results are high

If your omega-6 to omega-3 ratio is elevated (commonly above ~10:1), this suggests your current dietary pattern provides substantially more omega-6 relative to omega-3 fats. While omega-6 fats are not inherently harmful, a very high ratio often reflects low omega-3 intake, which may limit inflammation-resolving capacity.

• Diet:

  • Prioritise increasing marine omega-3 intake.

  • Aim for 3–4 servings of fatty fish per week (such as salmon, sardines, anchovies, mackerel, or herring), providing approximately 1,000–2,000 mg EPA+DHA per day.

  • Reduce reliance on omega-6-rich vegetable oils by choosing cooking fats with lower omega-6 content where possible, and limit highly processed foods and restaurant meals prepared with seed oils.

• Lifestyle: Support metabolic health through regular physical activity, adequate sleep, and stress management, as insulin resistance and inflammation can worsen fatty acid balance.

• Supplements: Marine omega-3 supplementation may be considered to increase EPA and DHA intake when dietary intake is insufficient, particularly in individuals who do not consume fish.

• Additional tests:

  • Measuring absolute omega-3 levels (EPA+DHA)

  • inflammatory markers

  • lipid profile

  • or triglycerides may provide additional context

If your results are low

If your omega-6 to omega-3 ratio is very low, this typically reflects high omega-3 intake relative to omega-6. This pattern is generally associated with anti-inflammatory effects and favourable cardiometabolic profiles.

• Diet: Continue a balanced intake of omega-3-rich foods while maintaining adequate overall energy and fat intake.

• Lifestyle: Maintain current physical activity and dietary habits that support metabolic health.

• Supplements: Ensure omega-3 intake remains appropriate rather than excessive, particularly if using high-dose supplements.

• Additional tests to consider: Periodic monitoring of fatty acid balance and lipid markers can help ensure long-term stability.

1. Schulze MB, Minihane AM, Saleh RNM, Risérus U. Intake and metabolism of omega-3 and omega-6 polyunsaturated fatty acids: nutritional implications for cardiometabolic diseases. The Lancet Diabetes & Endocrinology. 2020;8(11):915–930. doi:10.1016/S2213-8587(20)30148-0.

2. Saini RK, Keum YS. Omega-3 and omega-6 polyunsaturated fatty acids: dietary sources, metabolism, and significance—a review. Life Sciences. 2018;203:255–267. doi:10.1016/j.lfs.2018.04.049.

3. Harwood JL. Polyunsaturated fatty acids: conversion to lipid mediators, roles in inflammatory diseases and dietary sources. International Journal of Molecular Sciences. 2023;24(10):8838. doi:10.3390/ijms24108838.

4. Weinberg RL, Brook RD, Rubenfire M, Eagle KA. Cardiovascular impact of nutritional supplementation with omega-3 fatty acids: JACC Focus Seminar. Journal of the American College of Cardiology. 2021;77(5):593–608. doi:10.1016/j.jacc.2020.11.060.

5. Heymsfield SB, Shapses SA. Guidance on energy and macronutrients across the life span. The New England Journal of Medicine. 2024;390(14):1299–1310. doi:10.1056/NEJMra2214275.

6. Schmitz G, Ecker J. The opposing effects of n-3 and n-6 fatty acids. Progress in Lipid Research. 2008;47(2):147–155. doi:10.1016/j.plipres.2007.12.004.

7. Simopoulos AP. The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. Experimental Biology and Medicine (Maywood). 2008;233(6):674–688. doi:10.3181/0711-MR-311.

8. Simopoulos AP. Evolutionary aspects of diet, the omega-6/omega-3 ratio and genetic variation: nutritional implications for chronic diseases. Biomedicine & Pharmacotherapy. 2006;60(9):502–507. doi:10.1016/j.biopha.2006.07.080.

9. Simopoulos AP. The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomedicine & Pharmacotherapy. 2002;56(8):365–379. doi:10.1016/S0753-3322(02)00253-6.

10. Crick DCP, Halligan SL, Davey Smith G, Khandaker GM, Jones HJ. The relationship between polyunsaturated fatty acids and inflammation: evidence from cohort and Mendelian randomization analyses. International Journal of Epidemiology. 2025;54(4):dyaf065. doi:10.1093/ije/dyaf065.

11. De Caterina R. n–3 fatty acids in cardiovascular disease. The New England Journal of Medicine. 2011;364(25):2439–2450. doi:10.1056/NEJMra1008153.

12. Chowdhury R, Steur M. Invited commentary: dietary polyunsaturated fatty acids and chronic systemic inflammation—a potentially intriguing link. American Journal of Epidemiology. 2015;181(11):857–860. doi:10.1093/aje/kwv023.

13. Grytten E, Laupsa-Borge J, Cetin K, et al. Inflammatory markers after supplementation with marine n-3 or plant n-6 PUFAs: a randomized double-blind crossover study. Journal of Lipid Research. 2025;66(4):100770. doi:10.1016/j.jlr.2025.100770.

14. Chiusolo S, Bork CS, Gentile F, et al. Adipose tissue n-3/n-6 fatty acids ratios versus n-3 fatty acids fractions as predictors of myocardial infarction. American Heart Journal. 2023;262:38–48. doi:10.1016/j.ahj.2023.03.019.

15. Zhuang P, Wang W, Wang J, Zhang Y, Jiao J. Polyunsaturated fatty acids intake, omega-6/omega-3 ratio and mortality: findings from two independent nationwide cohorts. Clinical Nutrition. 2019;38(2):848–855. doi:10.1016/j.clnu.2018.02.019.

16. Lazic M, Inzaugarat ME, Povero D, et al. Reduced dietary omega-6 to omega-3 fatty acid ratio and 12/15-lipoxygenase deficiency are protective against chronic high fat diet-induced steatohepatitis. PLOS One. 2014;9(9):e107658. doi:10.1371/journal.pone.0107658.

17. Gutierrez-Guerra A, Cambron-Mora D, Rodriguez-Echevarria R, et al. Dietary n-6:n-3 PUFA ratio modulates inflammation-related gene expression and influences improvements in biochemical parameters in a murine model of diet-induced obesity. Nutrients. 2025;17(12):1996. doi:10.3390/nu17121996.

18. Wei Y, Meng Y, Li N, Wang Q, Chen L. The effects of low-ratio n-6/n-3 PUFA on biomarkers of inflammation: a systematic review and meta-analysis. Food & Function. 2021;12(1):30–40. doi:10.1039/d0fo01976c.

19. Jurado-Fasoli L, Osuna-Prieto FJ, Yang W, et al. High omega-6/omega-3 fatty acid and oxylipin ratio in plasma is linked to an adverse cardiometabolic profile in middle-aged adults. The Journal of Nutritional Biochemistry. 2023;117:109331. doi:10.1016/j.jnutbio.2023.109331.

20. Freeman AM, Morris PB, Aspry K, et al. A clinician’s guide for trending cardiovascular nutrition controversies: Part II. Journal of the American College of Cardiology. 2018;72(5):553–568. doi:10.1016/j.jacc.2018.05.030.

21. Abdelhamid AS, Brown TJ, Brainard JS, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews. 2020;3:CD003177. doi:10.1002/14651858.CD003177.pub5.

22. Vergara Nieto ÁA, Díaz AH, Hernández Millán M, Sagredo D. Molecular features, effective sources, and physiological effects of omega-3 unsaturated fatty acids on cardiovascular, neurological, and muscular health, and clinical relevance for several conditions: a narrative review. Nutrition Reviews. 2025;nuaf201. doi:10.1093/nutrit/nuaf201.

23. Santos HO, Price JC, Bueno AA. Beyond fish oil supplementation: the effects of alternative plant sources of omega-3 polyunsaturated fatty acids upon lipid indexes and cardiometabolic biomarkers—an overview. Nutrients. 2020;12(10):E3159. doi:10.3390/nu12103159.

24. Sanders TA. Plant compared with marine n-3 fatty acid effects on cardiovascular risk factors and outcomes: what is the verdict? The American Journal of Clinical Nutrition. 2014;100(Suppl 1):453S–458S. doi:10.3945/ajcn.113.071555.

25. Gutierres D, Pacheco R, Reis CP. The role of omega-3 and omega-6 polyunsaturated fatty acid supplementation in human health. Foods (Basel). 2025;14(19):3299. doi:10.3390/foods14193299.